Impact of interstitial lung disease on survival for patients with non-small cell lung cancer

Anticancer Research

Volumn 29, Issue 7, 2009, Pages 2671-2674

  Miyazaki, Kunihiko ^a   Satoh, Hiroaki ^a   Kurishima, Koichi ^a   Nakamura, Ryota ^a   Ishikawa, Hiroichi ^b   Kagohashi, Katsunori ^a   Ohara, Gen ^a   Hizawa, Nobuyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

Author keywords

Interstitial lung disease; Non small cell lung cancer; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 69249174126     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pirozynski M: One hundred years of lung cancer. Respir Med 100: 2073-2084, 2006. (Pubitemid 44718401)
2. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA and Socinski MA: Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2: 845-853, 2007. (Pubitemid 47361027)
3. Baumgartner KB, Samet JM, Stidley CA, Colby TV and Waldron JA: Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 155: 242-248, 1997. (Pubitemid 27053171)
4. Gustafson T, Dahlman-Höglund A, Nilsson K, Ström K, Tornling G and Torén K: Occupational exposure and severe pulmonary fibrosis. Respir Med 101: 2207-2212, 2007. (Pubitemid 47324247)
5. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997. (Pubitemid 27260107)
6. Chiyo M, Sekine Y, Iwata T, Tatsumi K, Yasufuku K, Iyoda A, Otsuji M, Yoshida S, Shibuya K, Iizasa T, Saitoh Y and Fujisawa T: Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 126: 1141-1146, 2003. (Pubitemid 37305703)
7. Kumar P, Goldstraw P, Yamada K, Nicholson AG, Wells AU, Hansell DM, Dubois RM and Ladas G: Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 125: 1321-1327, 2003. (Pubitemid 36759232)
8. Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383, 1987. (Pubitemid 17055592)
9. Cox DR: Regression models and life tables. J Roy Stat Soc B 34: 187-220, 1972.
10. Katzenstein AL, Mukhopadhyay S and Myers JL: Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol 39: 1275-1294, 2008.
11. Turner-Warwick M, Lebowitz M, Burrows B and Johnson A: Cryptogenic fibrosing alveolitis and lung cancer. Thorax 30: 496-499, 1980. (Pubitemid 10039553)
12. Hubbard R, Venn A, Lewis S and Britton J: Lung cancer and cryptogenic fibrosing alveolitis: A population-based cohort study. Am J Respir Crit Care Med 161: 5-8, 2000. (Pubitemid 30055895)
13. Park J, Kim DS, Shim TS, Lim CM, Koh Y, Lee SD, Kim WS, Kim WD, Lee JS and Song KS: Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 17: 1216-1219, 2001. (Pubitemid 32717481)
14. Firat S, Byhardt RW and Gore E: Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 54: 357-364, 2002.
15. Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat MC, Daurès JP, Pujol JL and OncoLR health network: A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 93: 1098-1105, 2005. (Pubitemid 41670692)
16. Madani I, De Ruyck K, Goeminne H, De Neve W, Thierens H and Van Meerbeeck J: Predicting risk of radiation-induced lung injury. J Thorac Oncol 2: 864-874, 2007. (Pubitemid 47361031)
17. Mehta V: Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63: 5-24, 2005. (Pubitemid 41583538)
18. Kong FM, Ten Haken R, Eisbruch A and Lawrence TS: Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 32(2 Suppl 3): S42-54, 2005. (Pubitemid 40626779)
19. Kato T and Nishio K: Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk. Respirology 11: 693-698, 2006. (Pubitemid 44581432)
20. Naito Y, Tsuchiya S, Ishihara S, Minato K, Shitara Y, Takise A, Suga T, Mogi A, Yamabe K and Saito R: Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease. Am J Clin Oncol 31: 340-344, 2008.
21. Yoneda KY, Shelton DK, Beckett LA and Gandara DR: Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2: 537-543, 2007.